Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

AMAG Pharmaceuticals Announces FDA Approval of Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena subcutaneous auto-injector drug-device combination product as a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

Ortho Dermatologics Announces U.S. FDA Filing Acceptance for Jemdel Plaque Psoriasis Treatment
LAVAL, Quebec, Feb. 14, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ( " Valeant " ), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves
The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopat ía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)
El 20 de enero del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una in fección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy
[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis Factor (TNF) blockers and malignancy (cancer) in children, adolescents, and young adults (30 years of age or younger). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Sudafed (Pseudoephedrine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
AUSTIN, Texas, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the resubmission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for Remoxy ER, its lead drug candidate. The... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Trump Budget Ups Funds to Fight Opioids, Cuts HHS Trump Budget Ups Funds to Fight Opioids, Cuts HHS
The budget takes a four-pronged approach, according to the new HHS secretary, with the fight against opioid abuse gaining some funding, while other departments may take some hits for 2019.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 13, 2018 Category: Drugs & Pharmacology Tags: Family Medicine/Primary Care News Source Type: news

FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
BOSTON--(BUSINESS WIRE) Feb 12, 2018 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

RPS in England advises the public to think 'pharmacy first' for minor health concerns
Today NHS Englandlaunched‘Stay Well Pharmacy’, a major new national media campaign to raise awareness and promote the use of community pharmacy for clinical advice for minor health concer (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

RPS advises the public to think 'pharmacy first' for minor health concerns
Today NHS Englandlaunched‘Stay Well Pharmacy’, a major new national media campaign to raise awareness and promote the use of community pharmacy for clinical advice for minor health concer (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter to healthcare professionals: Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and r (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Prandimet (Repaglinide and Metformin HCl Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Kyleena (levonorgestrel) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer ’s Third-generation ALK Inhibitor Lorlatinib
February 12, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company ’s New Drug Application for lorlatinib. Lorlatinib is an investigational, anaplastic... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that the United... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse
CORAL GABLES, Fla., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
CRANBURY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Efficacy of Fecal Microbiota Transplant in Refractory UC Efficacy of Fecal Microbiota Transplant in Refractory UC
Could the microbial composition of donor stools influence why some therapy refractory ulcerative colitis patients respond well to fecal transplantation, while others do not?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 9, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

RPS in Scotland welcomes funding for dedicated posts for care home pharmacists in England but urges quicker progress in Scotland
Earlier this week, NHS England announced that the Pharmacy Integration Fund will be used to fund 180 pharmacists and 60 pharmacy technician posts to help improve medicines optimisation (pharmaceutical (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

NHS England vaccine ordering for 2018-19 influenza season
NHS England have shared letters have with... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events
[10-24-2011] The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix (varenicline). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone
[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

Drug safety update: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients. It is now reco (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

Considerations for Statin Use, Toxicity, and Interactions Considerations for Statin Use, Toxicity, and Interactions
This brief primer gives an overview of the specific pharmacology for the various statin drugs, their adverse effects, and potential for drug interactions.Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 9, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Salix Provides Update on FDA Submission for Plenvu
BRIDGEWATER, N.J., Feb. 9, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Ltd. ( " Salix " ), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 9, 2018 Category: Drugs & Pharmacology Source Type: news

Device that measures cell strength could help identify drugs for asthma, hypertension and muscular dystrophy
Engineers, doctors and scientists at UCLA and Rutgers University have developed a tool that measures the physical strength of individual cells 100 times faster than current technologies.The new device could make it easier and faster to test and evaluate new drugs for diseases associated with abnormal levels of cell strength, including hypertension, asthma and muscular dystrophy. It could also open new avenues for biological research into cell force. It is the first high-throughput tool that can measure the strength of thousands of individual cells at a time.“Our tool tracks how much force individual cells exert over ...
Source: UCLA Newsroom: Health Sciences - February 9, 2018 Category: Universities & Medical Training Source Type: news

Avoiding Adverse Drug Interactions Can Prevent Hospitalizations in...
Twice as many patients aged 65 years and older are hospitalized because of problems related to an adverse drug reaction than younger patients, according to the...(PRWeb February 09, 2018)Read the full story at http://www.prweb.com/releases/2018/02/prweb15183047.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 9, 2018 Category: Pharmaceuticals Source Type: news

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

Dorzolamide Hydrochloride and Timolol Maleate (Cosopt) Ophthalmic Solution (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

Videx EC (Didanosine Delayed-Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

60 ° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria Drug
WASHINGTON, Feb. 8, 2018 /PRNewswire/ -- 60 Degrees Pharmaceuticals (60P) received Priority Review Designation from the United States Food and Drug Administration (USFDA) for Tafenoquine (TQ) for prevention of malaria in adults. The FDA... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

Tobacco giant's research largesse ignites controversy
(Source: ScienceNOW)
Source: ScienceNOW - February 8, 2018 Category: Science Authors: Enserink, M. Tags: Pharmacology, Toxicology, Scientific Community In Depth Source Type: news

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
[1-12-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Balcoltra (Levonorgestrel and Ethinyl Estradiol and Ferrous Bisglycinate Tablets ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Firvanq (Vancomycin Hydrochloride for Oral Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Lutathera (Lutetium Lu 177 dotatate Injection ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Verastem Submits NDA to FDA for Duvelisib for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
BOSTON--(BUSINESS WIRE)--Feb. 7, 2018-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application (NDA) to the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Re-introducing an 'old' antibiotic may help fight multi-drug resistant bacteria
(Wiley) A new study indicates that the drug fosfomycin may be effective for treating multidrug-resistant bacterial infections. In most European countries, the oral formulation is only approved as a 3 gram single dose for the treatment of uncomplicated cystitis; however the Pharmacology Research& Perspectives study found that a dosing regimen of 6-12 grams per day divided in 3 doses is required for the treatment of systemic multi-drug-resistant bacterial infections. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2018 Category: International Medicine & Public Health Source Type: news

SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Remifentanil (Ultiva) Lyophilized Powder for Solution Injection (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Fluorescein Strips (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Simvastatin (Zocor) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Saquinavir Mesylate (Invirase) 200mg Capsules (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Simvastatin Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Our media highlights 2017
We make every effort to get pharmacists on TV and radio speaking up about medicines and patient care. So how often do pharmacists appear in the media? If they're a member talking on behalf of the (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Changes to Ribena
Lucozade Ribena Suntory (LRS) are reducing the sugar content of Ribena Blackcurrant (Ready To Drink and squash by approximately 55%). Pharmacists should be aware of this change as Ribena Blackcurrant (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 6, 2018 Category: Drugs & Pharmacology Source Type: news

Safe Use Initiative - Current Projects
Part of Safe Use Initiative (updated) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 6, 2018 Category: Drugs & Pharmacology Source Type: news